Ustekinumab Efficacy in Children with Palmoplantar Psoriasis: Case Series

Background. Management with genetically engineered biologic drugs is recommended for patients with palmoplantar psoriasis when standard external therapy, physical therapy, and classical immunosuppressants lack efficacy. We present the results of ustekinumab administration in children with palmoplantar psoriasis resistant to standard therapy. Clinical case description. The results of ustekinumab administration in 12 children with palmoplantar psoriasis are presented. No comorbid pathologies were revealed in these patients during further examination. Thus, genetically engineered biologic therapy with ustekinumab (45 mg subcutaneously according to the recommended treatment regimen) was initiated due to the absence of any contraindications. 58.33% of all patients have achieved lower scores of PASI 90 index 12 weeks after therapy initiation. Conclusion. Management with genetically engineered biologic drugs such as ustekinumab (according to recommended regimen) may be suggested for patients with palmoplantar psoriasis due to its systemic chronic pathological process and lesions of functionally significant areas and in cases when standard external therapy, physical therapy, and classical immunosuppressants lack efficacy, in the absence of contraindications.

1. Gunter NV, Yap BJM, Chua CLL, Yap WH. Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients. Front Genet. 2019;10:395. doi: https://doi.org/10.3389/fgene.2019.00395

2. Murashkin NN, Kruglova LS, Kovalenko IA, et al. Psoriasis Comorbidities in Childhood. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(6):460–467. (In Russ). doi: https://doi.org/10.15690/vsp.v19i6.2149

3. Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: https://doi.org/10.1111/pde.13772

4. Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8:743180. doi: https://doi.org/10.3389/fmed.2021.743180

5. Kang BY, O’Haver J, Andrews ID. Pediatric Psoriasis Comorbidities: Screening Recommendations for the Primary Care Provider. J Pediatr Health Care. 2021;35(3):337–350. doi: https://doi.org/10.1016/j.pedhc.2020.12.006

6. Branisteanu DE, Georgescu S, Serban IL, et al. Management of psoriasis in children (Review). Exp Ther Med. 2021;22(6):1429. doi: https://doi.org/10.3892/etm.2021.10864

7. Elvina M. Pediatric Psoriasis: Clinical Features and Course. Open Acc J Bio Sci. 2020;1(5):207–209. doi: https://doi.org/10.38125/OAJBS.000147

8. Montes de Oca Pedrosa A, Oakley A, Rogers J, Rangaitaha Epiha M. PASI vs PO-PASI: Patient-Oriented PASI (PO-PASI) is comparable to clinician score PASI. Australas J Dermatol. 2022;63(1):e67–e70. doi: https://doi.org/10.1111/ajd.13738

9. Torrelo A. The use of biologics for childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1816. doi: https://doi.org/10.1111/jdv.15855. PMID: 31617632

10. Ivanov RA, Murashkin NN. Biological Therapy Survivability in Children with Psoriasis: Cohort Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):451–458. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2323

11. Murashkin NN, Ambarchian ET. Comparative Evaluation of the Treatment Efficacy and Safety of TNFα and IL12/23 Inhibitors in Children With Psoriasis. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2018;15(6):455–463. (In Russ). doi: https://doi.org/10.15690/pf.v15i6.1983

12. Murashkin NN, Ambarchian ET, Epishev RV, et al. Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(6):531–537. (In Russ). doi: https://doi.org/10.15690/vsp.v19i6.2153

13. Chovatiya R, Silverberg JI. Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. Children (Basel). 2019;6(10):108. doi: https://doi.org/10.3390/children6100108

14. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production 215 of interleukin-17. J Biol Chem. 2003;278(3):1910–1914. doi: https://doi.org/10.1074/jbc.M207577200

15. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. doi: https://doi.org/10.1084/jem.20030451

16. Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: A systematic review and meta-analysis. Pediatr Dermatol. 2022;39(1):42–48. doi: https://doi.org/10.1111/pde.14870

17. Paller AS, Siegfried EC, Langley RG, et al. Long-Term Safety and Efficacy of Etanercept in Children and Adolescents with Plaque Psoriasis. J Am Acad Dermatol. 2016;74(2):280–287.e1–e3. doi: https://doi.org/10.1016/j.jaad.2015.09.056

18. Papp K, Thaçi D, Marcoux D, et al. Efficacy and Safety of Adalimumab Every Other Week versus Methotrexate Once Weekly in Children and Adolescents with Severe Chronic Plaque Psoriasis: a Randomised, Double-Blind, Phase 3 Trial. Lancet. 2017;390(10089):40–49. doi: https://doi.org/10.1016/S0140- 6736(17)31189-3

19. Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–672. doi: https://doi.org/10.1111/bjd.19018

20. Magnolo N, Kingo K, Laquer V, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1): 122–130. doi: https://doi.org/10.1016/j.jaad.2021.08.066